Open AccessCost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
Author(s) -
Yafei Shi,
Wei Chen,
Yujun Zhang,
Mingming Bo,
Chunyu Li,
Mingyu Zhang,
Guohui Li
Publication year - 2021
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm-21-4178
Subject(s) - pembrolizumab , medicine , docetaxel , lung cancer , oncology , cost effectiveness , cancer , immunotherapy , risk analysis (engineering)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom